Matchpoint Therapeutics

Series-B+
matchpointtx.com Biotech & Healthcare Cambridge, United States Founded 2021 11-50
Total Funding $250M
Latest Round $150M Series-B+
Last Announced Oct 7, 2026
Investors 13 Backers
Decision Makers 6 Verified

About Matchpoint Therapeutics

Matchpoint Therapeutics discovers precision small molecule medicines that use covalency to treat immune diseases and other serious illnesses. The company uses its Advanced Covalent Exploration platform, which integrates chemoproteomics, machine learning, and covalent chemistry library evolution. Matchpoint has an emerging pipeline of novel covalent medicines.

Company Details

Intelligence Dossier

Corporate & Operational Profile

Primary Industry Biotech & Healthcare
Funding Stage Series-B+
Global Headquarters Cambridge, United States
Year Founded 2021
Team Size 11-50
Tracked Since Oct 8, 2026

Web & Domain Identity

Official Website matchpointtx.com
Domain Registered Date Dec 1, 2021

Social & Network Presence

X / Twitter Profile @matchpointtx (134 followers) Created on Jan 2022
LinkedIn Corporate Company Profile

Company Milestones & Timeline

5 Events
  1. Capital Raise

    Raised $150,000,000 · Series-B

    Backed by Nextech Invest, Norwest Venture Partners

  2. Capital Raise

    Raised $100,000,000 · Series-A

    Backed by Sanofi Ventures, Access Biotechnology

  3. Milestone

    X account created (@matchpointtx)

    134 followers

  4. Milestone

    Website domain registered

    matchpointtx.com

  5. Milestone

    Company founded

    Cambridge, United States

Investors & Backers

13
Access Biotechnology
Alexandria Venture Investments
Atlas Venture
BB Biotech
BOLD Longevity Growth Fund
citybiz
Digitalis Ventures
Invus
Nextech Invest
Norwest Venture Partners
Sanofi Ventures
T1D Fund
Vertex Ventures HC

Funding History

2 Rounds
Series-B equity · Oct 7, 2026

Round backers: Nextech Invest, Norwest Venture Partners, Access Biotechnology, Atlas Venture, BB Biotech, BOLD Longevity Growth Fund, Digitalis Ventures, Invus, Sanofi Ventures, T1D Fund

$150,000,000 bioworld.com
Series-A equity · Oct 17, 2022

Round backers: Sanofi Ventures, Access Biotechnology, Alexandria Venture Investments, Atlas Venture, Digitalis Ventures, Vertex Ventures HC, citybiz

$100,000,000 news.google.com

Founders & Leadership

6

Edward Chouchani

Founder

Work email & phone locked Unlock →

G. Andre Turenne

President and CEO

Work email & phone locked Unlock →

Jared Cumming

Chief Scientific Officer

Work email & phone locked Unlock →

Jianwei Che

Founder

Work email & phone locked Unlock →

Nathanael Gray

Founder

Work email & phone locked Unlock →

Tinghu Zhang

Founder

Work email & phone locked Unlock →

Press Coverage & Sources

Recently Funded Biotech & Healthcare Startups

View all

Search the startup feeds free with 50 starter credits.

START FREE WITH 50 CREDITS
Recently funded startups
New SaaS launches
Never pay twice for contacts